KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.

Othman Al-Sawaf, Brittany Gentile, Jacob Devine, Can Zhang, Kavita Sail, Maneesh Tandon, Anna-Maria Fink, Nadine Kutsch, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Hallek, Kirsten Fischer

Am J Hematol 96(9) 1112-1119

PMID34050972
PMCID-
DOI10.1002/ajh.26260
发表日期2021-05-29
入排依据:The study is a Phase III randomized trial of a drug combination in oncology, but the reported results are focused exclusively on patient-reported quality of life outcomes (EORTC QLQ-C30, MDASI). No time-to-event efficacy endpoint (like OS or PFS) is reported or analyzed in this specific abstract. Therefore, it does not meet the primary criterion for inclusion as a KM/HR study.
摘要

摘要

Chronic lymphocytic leukemia (CLL)-related symptoms impair the well-being of patients, making improvement of health-related quality of life (QoL) a goal of treatment. The CLL14 trial demonstrated higher efficacy of fixed-duration venetoclax-obinutuzumab (Ven-Obi) compared to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated CLL. To assess patients' QoL, the following patient-reported outcomes (PRO) measures were assessed: the M.D. Anderson Symptom Inventory (MDASI) core instrument and CLL module and the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). At treatment start, physical functioning (mean 75.9 [standard deviation (SD) ± 20.1] in the Clb-Obi arm and 76.9 [±19.4] in the Ven-Obi arm), role functioning (73.6 [±27.86] and 72.6 [±26.9]) and GHS/QoL (63.6 [±21.0] and 60.3 [±20.5]) were comparable between treatment arms per EORTC QLQ-C30 scale scores. Baseline levels of physical and role functioning were maintained throughout treatment and follow-up, with no relevant improvement or deterioration. On average, patients treated with Ven-Obi showed a meaningful improvement of GHS/QoL during treatment and follow-up by at least eight points at cycle three, whereas improvement was delayed until cycle eight with Clb-Obi. According to MDASI scores, CLL symptoms (1.5 [±1.2] and 1.6 [±1.3]), core cancer symptoms (1.5 [±1.4] and 1.8 [±1.7]) and symptom interference (2.1 [±2.3] and 2.3 [±2.3]) were generally low and comparable between treatment arms at baseline and were maintained throughout treatment and follow-up. This analysis demonstrates that the higher efficacy of Ven-Obi is not associated with QoL impairment and that Ven-Obi achieves early relief of CLL-related symptoms in elderly unfit patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。